• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

成功使用 casirivimab/imdevimab 抗刺突单克隆抗体增强了一名接受抗 CD20 治疗的难治性 COVID-19 女性的中和抗体。

Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.

机构信息

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.

出版信息

J Infect Chemother. 2022 Jul;28(7):991-994. doi: 10.1016/j.jiac.2022.03.002. Epub 2022 Mar 23.

DOI:10.1016/j.jiac.2022.03.002
PMID:35337728
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8940576/
Abstract

Management of COVID-19 patients with humoral immunodeficiency is challenging. We describe a woman with COVID-19 with multiple relapses due to anti-CD20 monoclonal antibody treatment. She was successfully treated with casirivimab/imdevimab and confirmed to have neutralizing antibodies. This case suggests that monoclonal antibodies have therapeutic and prophylactic value in patients with humoral immunodeficiency.

摘要

COVID-19 伴有体液免疫缺陷患者的管理颇具挑战。我们描述了一例 COVID-19 患者，因抗 CD20 单克隆抗体治疗而多次复发。该患者使用 casirivimab/imdevimab 治疗后成功康复，并检测到中和抗体。该病例提示，对于体液免疫缺陷患者，单克隆抗体具有治疗和预防价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574c/8940576/a99648b679bf/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574c/8940576/2a063e708e2d/gr1a_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574c/8940576/a99648b679bf/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574c/8940576/2a063e708e2d/gr1a_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574c/8940576/a99648b679bf/gr2_lrg.jpg

相似文献

1
Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.成功使用 casirivimab/imdevimab 抗刺突单克隆抗体增强了一名接受抗 CD20 治疗的难治性 COVID-19 女性的中和抗体。
J Infect Chemother. 2022 Jul;28(7):991-994. doi: 10.1016/j.jiac.2022.03.002. Epub 2022 Mar 23.
2
Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.成功早期使用抗 SARS-CoV-2 单克隆中和抗体治疗 SARS-CoV-2 感染的血液病患者：一项捷克多中心经验。
Hematol Oncol. 2022 Apr;40(2):280-286. doi: 10.1002/hon.2974. Epub 2022 Feb 17.
3
Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.卡司瑞韦单抗和伊德维单抗皮下注射或静脉给药与 COVID-19 成年患者临床结局的关联。
JAMA Netw Open. 2022 Apr 1;5(4):e226920. doi: 10.1001/jamanetworkopen.2022.6920.
4
The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19.中和单克隆抗体在 COVID-19 轻症至中度移植受者中的疗效。
Transpl Immunol. 2023 Apr;77:101777. doi: 10.1016/j.trim.2022.101777. Epub 2022 Dec 28.
5
Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.轻症至中度 COVID-19 高疾病进展风险非住院患者中不同单克隆抗体方案的临床疗效：一项前瞻性队列研究。
Eur J Clin Microbiol Infect Dis. 2022 Jul;41(7):1065-1076. doi: 10.1007/s10096-022-04464-x. Epub 2022 Jun 21.
6
Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.针对严重急性呼吸综合征冠状病毒 2 株 delta 和 omicron 变异株的单克隆抗体的临床疗效和体外中和能力。
J Med Virol. 2022 Oct;94(10):5038-5043. doi: 10.1002/jmv.27916. Epub 2022 Jun 11.
7
Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Coronavirus Disease 2019 (COVID-19).妊娠期新型冠状病毒病 2019（COVID-19）使用 Casirivimab 和 Imdevimab 的单克隆抗体。
Obstet Gynecol. 2021 Dec 1;138(6):937-939. doi: 10.1097/AOG.0000000000004603.
8
COVID-19 Updates: Monoclonal Antibodies for COVID-19.新冠疫情最新消息：用于治疗新冠的单克隆抗体
Med Lett Drugs Ther. 2022 Jan 24;64(1642):16.
9
Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.继发抗体缺陷患者中持续的 SARS-CoV-2 感染：使用 casirivimab 和 imdevimab（REGN-COV2）单克隆抗体联合治疗后成功清除。
Ann Clin Microbiol Antimicrob. 2021 Dec 30;20(1):85. doi: 10.1186/s12941-021-00491-2.
10
Casirivimab/Imdevimab: First Approval.卡司瑞韦单抗/伊德韦单抗：美国首次批准
Drugs. 2021 Nov;81(17):2047-2055. doi: 10.1007/s40265-021-01620-z.

引用本文的文献

1
Vaxtherapy, a Multiphase Therapeutic Protocol Approach for Longvax, the COVID-19 Vaccine-Induced Disease: Spike Persistence as the Core Culprit and Its Downstream Effects.疫苗疗法，一种针对新冠疫苗诱导疾病Longvax的多阶段治疗方案：刺突蛋白持续存在作为核心罪魁祸首及其下游影响
Diseases. 2025 Jun 30;13(7):204. doi: 10.3390/diseases13070204.
2
Successful 30-Day Nirmatrelvir/Ritonavir Treatment of a Patient Who Developed Multi-relapsed COVID-19 After Receiving R-CHOP Against Follicular Lymphoma.尼马曲韦/利托那韦成功治疗1例接受R-CHOP方案治疗滤泡性淋巴瘤后发生多次复发新型冠状病毒肺炎的患者
Cureus. 2025 Feb 14;17(2):e79019. doi: 10.7759/cureus.79019. eCollection 2025 Feb.
3

本文引用的文献

1
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.卡司瑞韦单抗和伊德韦单抗联合治疗住院 COVID-19 患者（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2022 Feb 12;399(10325):665-676. doi: 10.1016/S0140-6736(22)00163-5.
2
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals.BNT162b2 疫苗接种者中和/SARS-CoV-2-S1 结合抗体反应与不良反应和免疫动力学的相关性。
Sci Rep. 2021 Nov 24;11(1):22848. doi: 10.1038/s41598-021-01930-y.
3
Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients.
High diagnostic accuracy of quantitative SARS-CoV-2 spike-binding-IgG assay and correlation with viral neutralizing activity.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突结合免疫球蛋白G（IgG）定量检测具有高度诊断准确性及其与病毒中和活性的相关性
Heliyon. 2024 Jan 13;10(2):e24513. doi: 10.1016/j.heliyon.2024.e24513. eCollection 2024 Jan 30.
利妥昔单抗治疗患者对 COVID-19 疫苗接种产生体液免疫应答受损的风险因素。
Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI163-SI168. doi: 10.1093/rheumatology/keab815.
4
Incidence, Clinical Presentation, Relapses and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Patients Treated With Anti-CD20 Monoclonal Antibodies.抗 CD20 单克隆抗体治疗患者严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的发生率、临床表现、复发和结局。
Clin Infect Dis. 2022 May 30;74(10):1786-1794. doi: 10.1093/cid/ciab700.
5
Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail.在一位 B 细胞耗竭相关的持续性（B-DEAP）COVID 患者中，使用 REGEN-COV 抗刺突单克隆抗体鸡尾酒成功清除了 300 天的 SARS-CoV-2 感染。
Viruses. 2021 Jun 23;13(7):1202. doi: 10.3390/v13071202.
6
Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis.体液免疫对 SARS-CoV-2 的作用及对 COVID-19 发病机制的影响。
Mol Cells. 2021 Jun 30;44(6):392-400. doi: 10.14348/molcells.2021.0075.
7
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.利妥昔单抗而非其他抗风湿疗法，与风湿性疾病患者对SARS-CoV-2疫苗的血清学反应受损有关。
Ann Rheum Dis. 2021 Oct;80(10):1357-1359. doi: 10.1136/annrheumdis-2021-220604. Epub 2021 May 11.
8
Neutralizing monoclonal antibodies for treatment of COVID-19.用于治疗 COVID-19 的中和单克隆抗体。
Nat Rev Immunol. 2021 Jun;21(6):382-393. doi: 10.1038/s41577-021-00542-x. Epub 2021 Apr 19.
9
Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19).COVID-19 住院患者中感染性病毒排出的持续时间和关键决定因素。
Nat Commun. 2021 Jan 11;12(1):267. doi: 10.1038/s41467-020-20568-4.
10
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.REGN-COV2，一种中和抗体鸡尾酒疗法，用于治疗门诊新冠患者。
N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17.